Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Nov-24 7:19 PM View:  | Palleiko Ben CHIEF EXECUTIVE OFFICER Director | Kalvista Pharmaceuticals, I... (KALV) | 18-Nov-24 | Option Sale | 14,400 | $9.26 | $133,294.00 | (5%) 281.0K to 266.6K | |
| 19-Nov-24 7:18 PM View: | Audhya Paul K. Chief Medical Officer | Kalvista Pharmaceuticals, I... (KALV) | 18-Nov-24 | Option Sale | 8,077 | $9.26 | $74,765.60 | (8%) 102.28K to 94.2K | |
| 19-Nov-24 7:18 PM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 18-Nov-24 | Option Sale | 7,192 | $9.26 | $66,572.80 | (7%) 97.17K to 89.98K | |
| 19-Nov-24 7:18 PM View: | Audhya Paul K. Chief Medical Officer | Kalvista Pharmaceuticals, I... (KALV) | 17-Nov-24 | Option Exercise | 18,531 | -- | -- | 22% 83.75K to 102.28K | |
| 19-Nov-24 7:18 PM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 17-Nov-24 | Option Exercise | 11,496 | -- | -- | 13% 85.68K to 97.17K | |
| 19-Nov-24 7:19 PM View: | Palleiko Ben CHIEF EXECUTIVE OFFICER Director | Kalvista Pharmaceuticals, I... (KALV) | 17-Nov-24 | Option Exercise | 30,198 | -- | -- | 12% 250.8K to 281.0K | |
| 10-Sep-24 8:31 PM View: | Palleiko Ben CHIEF EXECUTIVE OFFICER Director | Kalvista Pharmaceuticals, I... (KALV) | 09-Sep-24 | Option Sale | 7,352 | $12.19 | $89,621.60 | (3%) 258.15K to 250.8K | |
| 10-Sep-24 8:31 PM View: | Palleiko Ben CHIEF EXECUTIVE OFFICER Director | Kalvista Pharmaceuticals, I... (KALV) | 06-Sep-24 | Option Exercise | 15,625 | -- | -- | 6% 242.53K to 258.15K | |
| 26-Aug-24 7:58 PM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 23-Aug-24 | Option Sale | 1,916 | $12.40 | $23,758.40 | (2%) 87.59K to 85.68K | |
| 26-Aug-24 8:00 PM View: | Audhya Paul K. Chief Medical Officer | Kalvista Pharmaceuticals, I... (KALV) | 23-Aug-24 | Option Sale | 2,135 | $12.40 | $26,474.00 | (2%) 85.88K to 83.75K | |
| 26-Aug-24 8:00 PM View: | Audhya Paul K. Chief Medical Officer | Kalvista Pharmaceuticals, I... (KALV) | 22-Aug-24 | Option Exercise | 5,000 | -- | -- | 6% 80.88K to 85.88K | |
| 26-Aug-24 7:58 PM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 22-Aug-24 | Option Exercise | 3,125 | -- | -- | 4% 84.47K to 87.59K | |
| 10-Jun-24 6:42 PM View: | Palleiko Ben CHIEF EXECUTIVE OFFICER Director | Kalvista Pharmaceuticals, I... (KALV) | 07-Jun-24 | Option Sale | 7,465 | $11.53 | $86,068.50 | (3%) 232.01K to 224.55K | |
| 10-Jun-24 6:42 PM View: | Palleiko Ben CHIEF EXECUTIVE OFFICER Director | Kalvista Pharmaceuticals, I... (KALV) | 06-Jun-24 | Option Exercise | 15,625 | -- | -- | 7% 216.39K to 232.01K | |
| 21-May-24 5:58 PM View: | Audhya Paul K. Chief Medical Officer | Kalvista Pharmaceuticals, I... (KALV) | 20-May-24 | Option Sale | 13,175 | $11.76 | $154,997.00 | (16%) 83.5K to 70.33K | |
| 21-May-24 5:59 PM View: | Feener Edward P. Chief Scientific Officer | Kalvista Pharmaceuticals, I... (KALV) | 20-May-24 | Option Sale | 8,088 | $11.76 | $95,151.30 | (10%) 80.95K to 72.86K | |
| 21-May-24 5:57 PM View: | Palleiko Ben CHIEF EXECUTIVE OFFICER Director | Kalvista Pharmaceuticals, I... (KALV) | 20-May-24 | Option Sale | 21,959 | $11.76 | $258,337.00 | (9%) 238.35K to 216.39K | |
| 21-May-24 5:55 PM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 20-May-24 | Option Sale | 11,610 | $11.76 | $136,586.00 | (13%) 91.68K to 80.07K | |
| 21-May-24 5:55 PM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 17-May-24 | Option Exercise | 18,789 | -- | -- | 26% 72.89K to 91.68K | |
| 21-May-24 5:58 PM View: | Audhya Paul K. Chief Medical Officer | Kalvista Pharmaceuticals, I... (KALV) | 17-May-24 | Option Exercise | 30,614 | -- | -- | 58% 52.89K to 83.5K | |
| 21-May-24 5:59 PM View: | Feener Edward P. Chief Scientific Officer | Kalvista Pharmaceuticals, I... (KALV) | 17-May-24 | Option Exercise | 18,789 | -- | -- | 30% 62.16K to 80.95K | |
| 21-May-24 5:57 PM View: | Palleiko Ben CHIEF EXECUTIVE OFFICER Director | Kalvista Pharmaceuticals, I... (KALV) | 17-May-24 | Option Exercise | 51,031 | -- | -- | 27% 187.31K to 238.35K | |
| 21-Feb-24 9:51 PM View: | Feener Edward P. Chief Scientific Officer | Kalvista Pharmaceuticals, I... (KALV) | 20-Feb-24 | Planned Option Sale | 10,391 | $14.05 | $145,961.00 | (13%) 82.05K to 71.66K | |
| 21-Feb-24 9:44 PM View: | Audhya Paul K. Chief Medical Officer | Kalvista Pharmaceuticals, I... (KALV) | 20-Feb-24 | Option Sale | 14,295 | $14.11 | $201,774.00 | (21%) 67.18K to 52.89K | |
| 21-Feb-24 9:51 PM View: | Feener Edward P. Chief Scientific Officer | Kalvista Pharmaceuticals, I... (KALV) | 20-Feb-24 | Sale (Planned) | 9,500 | $14.05 | $133,446.00 | (13%) 71.66K to 62.16K | |
| 21-Feb-24 9:46 PM View: | Palleiko Ben CFO, CBO | Kalvista Pharmaceuticals, I... (KALV) | 20-Feb-24 | Option Sale | 22,802 | $14.11 | $321,846.00 | (11%) 210.12K to 187.31K | |
| 21-Feb-24 9:51 PM View: | Feener Edward P. Chief Scientific Officer | Kalvista Pharmaceuticals, I... (KALV) | 20-Feb-24 | Option Sale | 8,397 | $14.11 | $118,522.00 | (9%) 90.44K to 82.05K | |
| 21-Feb-24 9:48 PM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 20-Feb-24 | Option Sale | 12,053 | $14.11 | $170,124.00 | (14%) 84.95K to 72.89K | |
| 21-Feb-24 9:41 PM View: | Crockett Thomas Andrew CEO Director | Kalvista Pharmaceuticals, I... (KALV) | 20-Feb-24 | Option Sale | 24,888 | $14.11 | $351,289.00 | (11%) 236.09K to 211.2K | |
| 21-Feb-24 9:41 PM View: | Crockett Thomas Andrew CEO Director | Kalvista Pharmaceuticals, I... (KALV) | 17-Feb-24 | Option Exercise | 54,415 | -- | -- | 30% 181.68K to 236.09K | |
| 21-Feb-24 9:51 PM View: | Feener Edward P. Chief Scientific Officer | Kalvista Pharmaceuticals, I... (KALV) | 17-Feb-24 | Option Exercise | 18,788 | -- | -- | 26% 71.66K to 90.44K | |
| 21-Feb-24 9:44 PM View: | Audhya Paul K. Chief Medical Officer | Kalvista Pharmaceuticals, I... (KALV) | 17-Feb-24 | Option Exercise | 30,613 | -- | -- | 84% 36.57K to 67.18K | |
| 21-Feb-24 9:46 PM View: | Palleiko Ben CFO, CBO | Kalvista Pharmaceuticals, I... (KALV) | 17-Feb-24 | Option Exercise | 51,029 | -- | -- | 32% 159.09K to 210.12K | |
| 21-Feb-24 9:48 PM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 17-Feb-24 | Option Exercise | 18,788 | -- | -- | 28% 66.16K to 84.95K | |
| 16-Feb-24 4:21 PM View: | Palleiko Ben CFO, CBO | Kalvista Pharmaceuticals, I... (KALV) | 14-Feb-24 | Private Sale | 40,855 | $15.01 | $613,205.00 | (20%) 199.94K to 159.09K | |
| 16-Feb-24 4:19 PM View: | Feener Edward P. Chief Scientific Officer | Kalvista Pharmaceuticals, I... (KALV) | 14-Feb-24 | Private Sale | 28,171 | $15.01 | $422,827.00 | (28%) 99.83K to 71.66K | |
| 16-Feb-24 4:18 PM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 14-Feb-24 | Private Sale | 39,886 | $15.01 | $598,661.00 | (38%) 106.05K to 66.16K | |
| 16-Feb-24 4:20 PM View: | Crockett Thomas Andrew CEO Director | Kalvista Pharmaceuticals, I... (KALV) | 14-Feb-24 | Private Sale | 58,356 | $15.01 | $875,883.00 | (24%) 240.03K to 181.68K | |
| 13-Feb-24 9:20 AM View: | Feener Edward P. Chief Scientific Officer | Kalvista Pharmaceuticals, I... (KALV) | 11-Feb-24 | Grant | 60,000 | -- | -- | 151% 39.83K to 99.83K | |
| 13-Feb-24 9:11 AM View: | Yea Christopher Chief Development Officer | Kalvista Pharmaceuticals, I... (KALV) | 11-Feb-24 | Grant | 60,000 | -- | -- | 130% 46.05K to 106.05K | |
| 13-Feb-24 9:23 AM View: | Palleiko Ben CFO, CBO | Kalvista Pharmaceuticals, I... (KALV) | 11-Feb-24 | Grant | 87,500 | -- | -- | 78% 112.44K to 199.94K | |
| 13-Feb-24 9:08 AM View: | Crockett Thomas Andrew CEO Director | Kalvista Pharmaceuticals, I... (KALV) | 11-Feb-24 | Grant | 122,500 | -- | -- | 104% 117.53K to 240.03K | |
| 08-Feb-24 8:11 PM View: | Venrock Healthcare Capital ... 10% Owner | Kalvista Pharmaceuticals, I... (KALV) | 08-Feb-24 | Purchase | 29,747 | $14.70 | $437,281.00 | < 1% 4.79M to 4.82M | |
| 08-Feb-24 8:11 PM View: | Venrock Healthcare Capital ... 10% Owner | Kalvista Pharmaceuticals, I... (KALV) | 07-Feb-24 | Purchase | 51,827 | $14.56 | $754,601.00 | 1% 4.74M to 4.79M | |
| 08-Feb-24 8:11 PM View: | Venrock Healthcare Capital ... 10% Owner | Kalvista Pharmaceuticals, I... (KALV) | 06-Feb-24 | Purchase | 4,474 | $14.74 | $65,946.80 | < 1% 4.74M to 4.74M | |
| 05-Feb-24 5:55 PM View: | Crockett Thomas Andrew CEO Director | Kalvista Pharmaceuticals, I... (KALV) | 01-Feb-24 | Private Sale (Planned) | 10,000 | $16.22 | $162,198.00 | (8%) 127.53K to 117.53K | |
| 01-Feb-24 4:38 PM View: | Venrock Healthcare Capital ... 10% Owner | Kalvista Pharmaceuticals, I... (KALV) | 30-Jan-24 | Purchase | 88,099 | $14.47 | $1,274,790.00 | 2% 4.65M to 4.74M | |
| 29-Jan-24 7:07 PM View: | Venrock Healthcare Capital ... 10% Owner | Kalvista Pharmaceuticals, I... (KALV) | 29-Jan-24 | Market Purchase | 80,600 | $14.22 | $1,146,130.00 | 2% 4.57M to 4.65M | (9%) |
| 29-Jan-24 7:07 PM View: | Venrock Healthcare Capital ... 10% Owner | Kalvista Pharmaceuticals, I... (KALV) | 26-Jan-24 | Market Purchase | 4,174 | $12.98 | $54,178.50 | < 1% 4.57M to 4.57M | (< 1%) |
| 29-Jan-24 7:07 PM View: | Venrock Healthcare Capital ... 10% Owner | Kalvista Pharmaceuticals, I... (KALV) | 25-Jan-24 | Market Purchase | 7,030 | $12.73 | $89,491.90 | < 1% 4.56M to 4.57M | 1% |
